Compare Live Nation Entertainment, Inc. (LYV) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Live Nation Entertainment, Inc. vs Zimmer Biomet Holdings Inc — how do they compare? Live Nation Entertainment, Inc. trades at $186.14 (market cap $43.17B), while Zimmer Biomet Holdings Inc trades at $99.52 (market cap $18.67B). The key difference: Live Nation Entertainment, Inc. is far larger — about 2.3× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays a 0.98% dividend while Live Nation Entertainment, Inc. pays none. Which is the better fit depends on your goals.
| LYV | ZBH | |
|---|---|---|
Market Cap | $43.17B | $18.67B |
Sector | Industrials | Health |
52-Week High | $186.59 | $107.71 |
52-Week Low | $125.61 | $79.58 |
Enterprise Value | $45.39B | $25.74B |
Dividend Yield | — | 0.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LYV trades at $186.06, up 1.49% in 24 hours, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates potential overbought conditions. Recent Q2 2026 earnings beat expectations with EPS of $1.05 versus $0.66 expected, driven by robust concert demand. Revenue grew 9% year-over-year, supported by record attendance and deferred revenue of $6.4 billion. Analyst consensus is overwhelmingly bullish with 87% buy ratings and a $209.54 price target.
Outlook remains positive due to sustained live event demand, but risks include high valuation (P/E 117.5), debt levels, and legal uncertainties. Net income margin compression to 0.51% in 2025 and negative ROE of -116.7% highlight profitability challenges. Insider stock sales in August 2026 suggest caution among executives despite strong fundamentals. The stock offers growth exposure to experiential spending trends but requires monitoring of execution and cost pressures.
Zimmer Biomet (ZBH) trades at $99.57, up 2.41% today, with a bullish technical signal and consistent earnings beats. Revenue grew to $8.23B in 2025, though net income margin declined to 8.56%. The stock is near resistance at $100, with a P/E of 23.76 and analyst consensus target of $103.56. Recent Q2 2026 results showed sales growth of 4.8% and an EPS beat.
Outlook is positive with raised 2026 guidance and strong institutional interest, but risks include margin pressure and high debt. Analysts are mixed with 40% buy ratings, highlighting growth in hips and robotics as key drivers. Investors should monitor execution against targets and debt management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Live Nation Entertainment, Inc.
Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
